RT Journal Article
SR Electronic
T1 Development of user-friendly consumer and health professional resources for the antipsychotic clozapine: a New Zealand example
JF BMJ Innovations
JO BMJ Innov
FD All India Institute of Medical Sciences
SP 17
OP 21
DO 10.1136/bmjinnov-2014-000006
VO 1
IS 1
A1 Nicola J Holmes
A1 S Wayne Miles
A1 Amanda J Wheeler
YR 2015
UL http://innovations.bmj.com/content/1/1/17.abstract
AB The antipsychotic clozapine has been shown to have superior efficacy to most other treatments for psychosis, especially where treatment-resistant schizophrenia has been diagnosed. Like all medications, clozapine has a number of well-recognised adverse effects, some of which can be fatal. Evidence also suggests that those for whom clozapine is the most suitable treatment option do not receive it because the doctor or health system views the risks as too great to prescribe. The provision of guidelines including innovative consumer and general practitioner resources regarding the ways to most safely monitor and manage people who are exposed to clozapine has the potential to increase the safe use of the product and also to provide potential prescribers with more confidence in using it. This paper outlines both the process for development and the final package produced by a large metropolitan District Health Board service in Auckland, New Zealand. This material was aimed at non-specialist prescribers as well as consumers and their family/carers and other supports.